UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.164

Sortiert nach

Measurements of Sea Clutter at Low Grazing Angle in Mediterranean Coastal Environment

IEEE transactions on geoscience and remote sensing, 2017-11, Vol.55 (11), p.6379-6389

2017

Link zum Volltext
Volltext

Fibrosis and disease progression in hepatitis C: Fibrosis and disease progression in hepatitis C

Hepatology (Baltimore, Md.), 2002-11, Vol.36 (5B), p.s47-s56

2002

Link zum Volltext

Verfügbarkeit prüfen

Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients

Journal of viral hepatitis, 2016-11, Vol.23 (11), p.905-911

2016

Link zum Volltext

Verfügbarkeit prüfen

Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C

Journal of viral hepatitis, 2012-04, Vol.19 (4), p.244-253

2012

Link zum Volltext

Verfügbarkeit prüfen

No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg− patients with chronic hepatitis B after 8 years of treatment

Journal of viral hepatitis, 2017-01, Vol.24 (1), p.68-74

2017

Link zum Volltext

Verfügbarkeit prüfen

STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER?

Gut, 2006-01, Vol.55 (1), p.123-130

2006

Link zum Volltext

Verfügbarkeit prüfen

Treatment of chronic hepatitis B

Journal of viral hepatitis, 2005-07, Vol.12 (4), p.333-345

2005

Link zum Volltext

Verfügbarkeit prüfen

Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C

Gut, 2008-04, Vol.57 (4), p.516-523

2008

Link zum Volltext

Verfügbarkeit prüfen

Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa‐2a combination therapy for chronic hepatitis B

Alimentary pharmacology & therapeutics, 2016-11, Vol.44 (9), p.957-966

2016

Link zum Volltext

Verfügbarkeit prüfen

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

Gut, 2007-05, Vol.56 (5), p.699-705

2007

Link zum Volltext

Verfügbarkeit prüfen

Shorter durations and lower doses of peginterferon alfa‐2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C

Hepatology (Baltimore, Md.), 2011-11, Vol.54 (5), p.1591-1599

2011

Link zum Volltext

Verfügbarkeit prüfen

Gene expression and hepatitis C virus infection

Gut, 2009-06, Vol.58 (6), p.846-858

2009

Link zum Volltext

Verfügbarkeit prüfen

Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4

Gut, 2009-12, Vol.58 (12), p.1662-1669

2009

Link zum Volltext

Verfügbarkeit prüfen

Long-term clearance of hepatitis C virus following interferon [alpha]-2b or peginterferon [alpha]-2b, alone or in combination with ribavirin

Journal of viral hepatitis, 2013-08, Vol.20 (8), p.524

2013

Link zum Volltext

Verfügbarkeit prüfen

Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection

Journal of viral hepatitis, 2007-07, Vol.14 (7), p.460-467

2007

Link zum Volltext

Verfügbarkeit prüfen

Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin

Journal of viral hepatitis, 2013-08, Vol.20 (8), p.524-529

2013

Link zum Volltext

Verfügbarkeit prüfen

HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg‐positive chronic hepatitis B patients

Alimentary pharmacology & therapeutics, 2018-01, Vol.47 (1), p.114-122

2018

Link zum Volltext

Verfügbarkeit prüfen

Whole-genome deep sequencing of hepatitis B virus in chronic hepatitis B patients reveals single nucleotide variants associated with baseline HBV DNA levels and HBeAg status

Journal of hepatology, 2017, Vol.66 (1), p.S679-S679

2017

Link zum Volltext

Verfügbarkeit prüfen

Whole-genome sequencing of patients achieving hepatitis B virus serum antigen loss following tenofovir disoproxil fumerate (TDF) and/or pegylated-interferon α-2a (PEG) therapy

Journal of hepatology, 2017, Vol.66 (1), p.S691-S691

2017

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of serum HBV RNA and HBcrAg in chronic hepatitis B patients achieving different serological outcomes on tenofovir disoproxil fumarate (TDF)

Journal of hepatology, 2017, Vol.66 (1), p.S476-S476

2017

Link zum Volltext

Verfügbarkeit prüfen

835 GLOBAL ANALYSIS OF LIVER MIRNAS EXPRESSION IN CHRONIC HEPATITIS C LEADING TO A SIGNATURE TO PREDICT RESPONSE TO TREATMENT

Journal of hepatology, 2012-04, Vol.56, p.S326-S326

2012

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP study

Epidemiology and infection, 2019-01, Vol.147, p.e234-e234, Article e234

2019

Link zum Volltext

Verfügbarkeit prüfen

IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients

Journal of viral hepatitis, 2014-07, Vol.21 (7), p.525-532

2014

Link zum Volltext

Verfügbarkeit prüfen

HCV eradication reduces the occurrence of major adverse cardiovascular events in hepatitis C cirrhotic patients: data from the prospective ANRS CO12 CirVir cohort

Journal of hepatology, 2017, Vol.66 (1), p.S20-S21

2017

Link zum Volltext

Verfügbarkeit prüfen

Treatment of hepatitis C. The 2002 French consensus

Gut, 2003-12, Vol.52 (12), p.1784-1787

2003

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.164

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(964)
Mit Volltextzugriff
(1.044)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(511)
Life Sciences & Biomedicine
(435)
Humans
(424)
Female
(277)
Male
(265)
Adult
(249)
Gastroenterology And Hepatology
(200)
Biological And Medical Sciences
(190)
Gastroenterology & Hepatology
(189)
Middle Aged
(189)
Medical Sciences
(182)
Infectious Diseases
(171)
Antiviral Agents - Therapeutic Use
(110)
Viral Diseases
(100)
Human Viral Diseases
(97)
Interferon-Alpha - Therapeutic Use
(94)
Viral Hepatitis
(79)
Aged
(77)
Hepatitis C Virus
(73)
Life Sciences
(71)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Hepatology
(327)
Hepatology
(75)
Gastroentérologie Clinique Et Biologique
(57)
Journal Of Viral Hepatitis
(41)
Journal Of Clinical Virology
(29)
Gut
(28)
Gastroenterology
(21)
Human Reproduction
(19)
La Revue De Medecine Interne
(18)
Alimentary Pharmacology & Therapeutics
(11)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Measurements of Sea Clutter at Low Grazing Angle in Mediterranean Coastal Environment

Fibrosis and disease progression in hepatitis C: Fibrosis and disease progression in hepatitis C

Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients

Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C

No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg− patients with chronic hepatitis B after 8 years of treatment

STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER?

Treatment of chronic hepatitis B

Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C

Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa‐2a combination therapy for chronic hepatitis B

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

Shorter durations and lower doses of peginterferon alfa‐2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C

Gene expression and hepatitis C virus infection

Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4

Long-term clearance of hepatitis C virus following interferon [alpha]-2b or peginterferon [alpha]-2b, alone or in combination with ribavirin

Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection

Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin

HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg‐positive chronic hepatitis B patients

Whole-genome deep sequencing of hepatitis B virus in chronic hepatitis B patients reveals single nucleotide variants associated with baseline HBV DNA levels and HBeAg status

Whole-genome sequencing of patients achieving hepatitis B virus serum antigen loss following tenofovir disoproxil fumerate (TDF) and/or pegylated-interferon α-2a (PEG) therapy

Evaluation of serum HBV RNA and HBcrAg in chronic hepatitis B patients achieving different serological outcomes on tenofovir disoproxil fumarate (TDF)

835 GLOBAL ANALYSIS OF LIVER MIRNAS EXPRESSION IN CHRONIC HEPATITIS C LEADING TO A SIGNATURE TO PREDICT RESPONSE TO TREATMENT

Hepatitis C subtype distribution in chronically infected patients with mild liver fibrosis in France: the GEMHEP study

IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients

HCV eradication reduces the occurrence of major adverse cardiovascular events in hepatitis C cirrhotic patients: data from the prospective ANRS CO12 CirVir cohort

Treatment of hepatitis C. The 2002 French consensus

Suchergebnisse filtern